All posts by: Michael Zand

Are Stem Cells The Future Of Medicine? – Anti Aging News

Anti Aging NewsAre Stem Cells The Future Of Medicine?Anti Aging NewsIn general, physicians and patients alike believe that stem cells are the future of medicine. According to Roger Pedersen, Professor of Regenerative Medicine and Director of the Anne … Continue reading

Are Stem Cells The Future Of Medicine? – Anti Aging News

Anti Aging NewsAre Stem Cells The Future Of Medicine?Anti Aging NewsIn general, physicians and patients alike believe that stem cells are the future of medicine. According to Roger Pedersen, Professor of Regenerative Medicine and Director of the Anne … Continue reading

ViaCyte Reports on Stem Cell Diabetes Trial, Absorbs BetaLogics – Xconomy

Xconomy

ViaCyte Reports on Stem Cell Diabetes Trial, Absorbs BetaLogics Xconomy In a deal that consolidates its position as a leader in developing a stem cell-derived treatment for diabetes, San Diego’s ViaCyte says today it is absorbing its chief rival, New Jersey-based Janssen BetaLogics. The asset deal comes in conjunction with … ViaCyte Acquires Rights to BetaLogics Assets, Expanding and Extending Industry-Leading Portfolio for Stem Cell …PR Newswire (press release) Johnson & Johnson, ViaCyte Testing Possible Diabetes CureABC News all 11 news articles »

Xconomy

ViaCyte Reports on Stem Cell Diabetes Trial, Absorbs BetaLogics Xconomy In a deal that consolidates its position as a leader in developing a stem cell-derived treatment for diabetes, San Diego’s ViaCyte says today it is absorbing its chief rival, New Jersey-based Janssen BetaLogics. The asset deal comes in conjunction with … ViaCyte Acquires Rights to BetaLogics Assets, Expanding and Extending Industry-Leading Portfolio for Stem Cell …PR Newswire (press release) Johnson & Johnson, ViaCyte Testing Possible Diabetes CureABC News all 11 news articles »

Xconomy

ViaCyte Reports on Stem Cell Diabetes Trial, Absorbs BetaLogics Xconomy In a deal that consolidates its position as a leader in developing a stem cell-derived treatment for diabetes, San Diego’s ViaCyte says today it is absorbing its chief rival, New Jersey-based Janssen BetaLogics. The asset deal comes in conjunction with … ViaCyte Acquires Rights to BetaLogics Assets, Expanding and Extending Industry-Leading Portfolio for Stem Cell …PR Newswire (press release) Johnson & Johnson, ViaCyte Testing Possible Diabetes CureABC News all 11 news articles »

Xconomy

ViaCyte Reports on Stem Cell Diabetes Trial, Absorbs BetaLogics Xconomy In a deal that consolidates its position as a leader in developing a stem cell-derived treatment for diabetes, San Diego’s ViaCyte says today it is absorbing its chief rival, New Jersey-based Janssen BetaLogics. The asset deal comes in conjunction with … ViaCyte Acquires Rights to BetaLogics Assets, Expanding and Extending Industry-Leading Portfolio for Stem Cell …PR Newswire (press release) Johnson & Johnson, ViaCyte Testing Possible Diabetes CureABC News Possible diabetes cure being tested on small number of patientsQ13 FOX all 47 news articles »

The Globe and Mail

Canadian ‘dream team’ to probe stem–cell link to brain cancer The Globe and Mail The cancer stem–cell hypothesis suggests that, over time, stem cells can accumulate a series of deleterious genetic changes that turn them into tumour-promoting cells. If so, it would explain why brain cancer can return after a tumour is removed. As … Stem Cell Research Products – Opportunities, Tools, And Technologies 2016: MarketResearchReports.BizMedgadget.com (blog) Global Stem Cell Research Products Strategic Report 2016 – Analysis, Technologies, Opportunities & Forecasts – BD …Business Wire (press release) International Stem Cell Corporation ($ISCO) Continues Upward Climb toward Changing the Face of Regenerative …InvestorIdeas.com (press release) all 11 news articles »

The Globe and Mail

Canadian ‘dream team’ to probe stem–cell link to brain cancer The Globe and Mail The cancer stem–cell hypothesis suggests that, over time, stem cells can accumulate a series of deleterious genetic changes that turn them into tumour-promoting cells. If so, it would explain why brain cancer can return after a tumour is removed. As … Stem Cell Research Products – Opportunities, Tools, And Technologies 2016: MarketResearchReports.BizMedgadget.com (blog) Global Stem Cell Research Products Strategic Report 2016 – Analysis, Technologies, Opportunities & Forecasts – BD …Business Wire (press release) International Stem Cell Corporation ($ISCO) Continues Upward Climb toward Changing the Face of Regenerative …InvestorIdeas.com (press release) all 11 news articles »